Hepatitis B reactivation among 1962 patients with hematological malignancy in Taiwan

The risk of Hepatitis B virus (HBV) reactivation in patients with different hematological malignancy except lymphoma were rarely known before. A total of 1962 patients with hematological malignancy were enrolled and followed-up at the National Taiwan University Hospital between 2008 and 2013. The cl...

Full description

Saved in:
Bibliographic Details
Published in:BMC gastroenterology 2018-01, Vol.18 (1), p.6-6, Article 6
Main Authors: Chen, Chien-Yuan, Tien, Feng-Ming, Cheng, Aristine, Huang, Shang-Yi, Chou, Wen-Chien, Yao, Ming, Tang, Jih-Luh, Tien, Hwei-Fang, Sheng, Wang-Huei
Format: Article
Language:English
Subjects:
Antiviral prophylaxis
Cancer
Cancer patients
Chemotherapy
Complications and side effects
Health aspects
Hematological malignancy
Hepatitis B
Hepatitis B reactivation
Lymphomas
Risk factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The risk of Hepatitis B virus (HBV) reactivation in patients with different hematological malignancy except lymphoma were rarely known before. A total of 1962 patients with hematological malignancy were enrolled and followed-up at the National Taiwan University Hospital between 2008 and 2013. The clinical characteristics, HBV serology, and laboratory data were retrospectively reviewed and analyzed. A total of 1962 patients comprising 1048 men and 914 women were studied. The median age of the patients was 55 years (range, 15-97 years). Chronic HBV carriage was documented at diagnosis of hematological malignancy in 286 (14.6%) patients. A total of 171 (59.8%) of the 286 HBV carriers received primary prophylaxis with anti-HBV agents. Of the HBV carriers, 97 (33.9%) developed hepatitis B reactivation during or after chemotherapy, including 59 patients who had discontinued antiviral therapy. The incidence of hepatitis B reactivation among patients with hematological malignancy and HBV carriage was 10.4 per 100 person-years. A multivariate analysis revealed hepatocellular carcinoma (p 
ISSN:1471-230X
1471-230X
DOI:10.1186/s12876-017-0735-1